GSK Form 6-K reports transactions for ISIN US37733W2044 on Aug 19, 2025

Rhea-AI Filing Summary

GSK plc submitted a Form 6-K reporting a transaction notification dated August 19, 2025. The filing identifies the security by ISIN US37733W2044 and lists three reported volumes: 3,328.441, 84, and 61.934. The report does not disclose prices, counterparty names, or the specific nature of each transaction in the supplied text. No financial amounts, proceeds, gains, or other narrative explanation appear in the provided content. Because key fields such as price and transaction description are not present, the filing records activity in the listed share lots but provides limited information to assess material investor impact.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$39.3600	3,328.441
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-08-15
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$39.3600	84
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-08-15
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$39.3600	61.934
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-08-15
f)	Place of the transaction	New York Stock Exchange (XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: August 19, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What did GSK (GSK) disclose in the Form 6-K dated August 19, 2025?

The filing is a transaction notification showing the security ISIN US37733W2044 and reported volumes of 3,328.441, 84, and 61.934.

Does the Form 6-K include transaction prices or counterparty names for GSK?

No. The provided content does not include any prices, counterparty names, or descriptions of the transactions.

Are the reported volumes in the Form 6-K likely to be material to investors?

The filing lists three volume figures but contains no price or context; the document itself does not state that these amounts are material.

Which ISIN is referenced in GSK's Form 6-K?

The filing references ISIN US37733W2044.

What is the date of the transaction notification in the Form 6-K?

The transaction notification is dated August 19, 2025.